I diopathic dilated cardiomyopathy (IDCM) is a severe myocardial disease characterized by dilatation and impaired function of the left or both ventricles, 1 affecting >36.5 individuals per 100 000. 2 IDCM accounts for ≈50 000 hospitalizations and 10 000 deaths each year and is responsible for ≈25% of all cases of heart failure (HF) in the United States. 3 During the past 3 decades, the outcome of IDCM is presumed to have radically changed after major advances in pharmacological and device-based therapeutic strategies for HF; however, studies addressing the outcome of HF have been characterized by relatively small representation of individuals with IDCM, so that limited data exist with specific regard to this condition. [4] [5] [6] [7] [8] [9] [10] [11] 
Clinical Perspective on 921
In addition, real-world implementation of standard HF guidelines is challenging, with rates of compliance that can be considerably lower than those reported in clinical trials documenting survival benefits. [12] [13] [14] [15] [16] [17] As a result, the issue of long-term outcome of IDCM in the community remains largely unresolved. In the present study, we therefore chose to examine the clinical features and prognosis of a sizeable cohort of unselected, consecutively enrolled and angiographically negative patients with IDCM from a well-defined regional population in Tuscany, evaluated during the past 30 years in a systematic fashion and by the same team, in relation to the evolving treatment strategies including evidence-based pharmacological and device-based interventions.
Methods

Setting and Study Population
The Referral Center for Cardiomyopathies has been established in the mid-1970s in Careggi University Hospital, a large community-based multispecialty hospital in Florence, Italy. Careggi is a tertiary center with >1500 beds, serving the Florence metropolitan area (population ≈1 million) and the surrounding geographic region of Tuscany (total population ≈3 700 000 within ≈23 000 km 2 ). 18 In this setting, between January 1977 and September 2011, we consecutively enrolled 1085 patients with a diagnosis of dilated cardiomyopathy. In 271 patients, the condition was judged to be secondary to ischemic heart disease, systemic hypertension, chemotherapy, alcoholic abuse, diabetes mellitus, cor pulmonalis, valve disease, or other cardiac or systemic diseases. In addition, 211 patients in whom a coronary angiogram was not available were excluded. The remaining 603 were classified as IDCM, according to the World Health Organization criteria and in the presence of a negative coronary angiogram: these comprise the present study cohort.
Evaluation and Follow-Up
All study patients were evaluated and followed up at our institution by clinical and family history, physical examination, 12-lead ECG, standard chest radiograph, routine laboratory tests, 24-hour Holter ECG monitoring (since early 1980s), M-mode and 2D echocardiography (since 1970s), and Doppler echocardiography (since mid-1980s). Exercise stress test and cardiac catheterization were performed as dictated by clinical requirements. Endomyocardial biopsy has been performed routinely until the early 1990s and thereafter only on selected patients with suspect active myocarditis. Although the family history of each patient was investigated, systematic family screenings have not been performed. In 51 patients (8%) a genetic transmission of IDCM was evident or suspected by virtue of clinical and echocardiographic documentation of the disease in a relative or by a family history of HF-related death or premature sudden death (SD).
Patients were regularly followed up by outpatient visits every 6 months (or more frequently when clinically indicated) and, when necessary, by interviews with referring physicians or by telephone contacts. For the purposes of this study, follow-up ended on September 30th, 2011. In patients who died or were transplanted, end of follow-up was considered as time of death or heart transplantation. In the minority of patients lost to follow-up (ie, not traceable by September 30th, 2011), the last clinical evaluation of telephone contact was considered. In the past 5 years of the study (2006) (2007) (2008) (2009) (2010) (2011) , the proportion of patients who were actively followed up, had died/ transplanted, or were lost in period was 44%, 45%, and 11%, respectively. For the entire study period, patients were seen by the same cardiologists who assumed primary responsibility for management. The use of pharmacological agents, implantable cardioverter defibrillator (ICD), and biventricular pacing for cardiac resynchronization therapy (CRT) was carefully considered as these became available and implemented when felt appropriate, according to existing guidelines. 19 Pharmacological treatment was carefully titered to achieve maximum tolerated doses of angiotensin-converting enzyme inhibitors/angiotensin receptors blockers (ACEI/ARBs) and β-blockers. Candidates for heart transplantation (HTx) were assessed jointly with the Regional Heart Transplant Referral Center in Siena, where the operations were performed. The study was approved by the institutional review committee and patients gave an informed consent.
Enrollment Periods
To assess long-term changes in outcome in relation to treatment options, we subdivided our patients with IDCM into 4 periods, coinciding with different therapeutic eras of HF treatment: period 1: 66 patients (11%) enrolled from 1977 to 1984, defined as the pre-ACE inhibition era, when standard therapy consisted of diuretic agents, digoxin, and early vasodilators; period 2: 102 patients (17%) enrolled from 1985 to 1990, marking the beginning of the ACEI era; period 3: 197 patients (33%) enrolled from 1991 to 2000, characterized by increasing use of ACEI and ARBs and the introduction of β-blockers; and period 4: 238 patients (39%) enrolled from 2001 to 2011, the device-era, characterized by the introduction of ICD and CRT on top of extensive neurohormonal blockade. 20
Statistical Analysis
Student t test and 1-way ANOVA were used to compare continuous variables, whereas categorical variables were compared by χ 2 test or Fisher method, as appropriate. Univariate survival estimates were obtained using Kaplan-Meier method. Forward conditional Cox proportional hazards regression analysis was used to evaluate the relationship between periods of enrollment, clinical and instrumental baseline data of patients, and long-term outcome for the following end points: (1) death from any cause including appropriate ICD interventions and HTx; (2) SD; (3) death because of refractory HF. The following variables were included in the models: age, New York Heart Association (NYHA) class, sex, left ventricular ejection fraction (LVEF), baseline LV end-diastolic diameter index, left atrial diameter index, and the presence of moderate to severe mitral regurgitation at enrollment. A P value <0.05 was considered statistically significant. Statistical analysis was performed with the SPSS package, version 20 (SPSS Inc, Chicago, IL).
Results
Baseline Clinical Features
Mean age of the 603 patients at first evaluation was 53±12 (range, 16-75) years; 442 (73%) were men. In 51 patients (8%) there was a family history of IDCM. Average NYHA functional class was 2.3±0.8; 82 patients (14%) were in class I, 265 (44%) in class II, 198 (33%), and 58 (10%) in class III or IV. Mean enddiastolic diameter index was 36±6 mm/m 2 , LVEF was 31±10%, and left atrial diameter index was 24±4 mm/m 2 ; moderate to severe mitral regurgitation was diagnosed in 106 patients (18%). One hundred seventeen patients (19%) had ECG evidence of left bundle-branch block, whereas a history of paroxysmal or permanent atrial fibrillation was recorded in 123 (21%). Of the 531 patients with 24-hour ambulatory Holter monitoring, 183 (30%) showed non-sustained ventricular tachycardias ≥3 beats and sustained ventricular tachycardias ( Table 1) .
Comparison of Enrollment Periods
At initial evaluation, the 4 groups of patients identified based on the period of enrollment were comparable with regard to sex and NYHA class (Table 1 ). However, there was a slight trend toward enrollment of older patients with less severe LV dilatation and dysfunction during the years: in period 4 versus period 1, age was 55±12 versus 50±11 years, respectively (P<0.0001); end-diastolic diameter index was 34±5 versus 39±6 mm/m 2 (P<0.0001), and LVEF was 33±9 versus 29±11% (P=0.016). The overall prevalence of atrial fibrillation was similar in the 4 periods; however, permanent atrial fibrillation at initial diagnosis became less prevalent over time (overall P<0.001; Table 1 ).
Evolution in Management
Expectedly, medical treatment at enrollment differed significantly between the 4 patient periods (Table 2; Figure 1 ). ACEI and ARBs were extensively used at our institution since early 1990s, reaching a 96% rate at enrollment after 2001 versus 4% before 1985 (P<0.0001). The use of β-blockers increased significantly after 2001: 79% of patients were already treated with these agents at enrollment in period 4 compared with 0% in period 1, 1% in period 2, and 21% in period 3 (P<0.0001). These differences were still evident at the end of follow-up, although the rate of treated patients considerably increased in all patient subgroups, reflecting changes in management over time ( Table 2 ). Of note, 97% and 86% of patients in period 4 were on ACEI/ARBs and β-blockers, respectively, at final evaluation. The use of mineralocorticoid receptor antagonists also increased progressively in periods 1 to 4, whereas that of digoxin decreased (at final evaluation, only 37% of patients in period 4 were on digoxin versus 92% in period 1; P<0.0001). The ICD and CRT were introduced in 1998 and 2000, respectively, and their use increased steadily over time (Table 2) . Overall, 79 patients (13%) were implanted with an ICD, whereas 69 (11%) received combined ICD/CRT ( Figure 1 ). Notably, 52% of patients that received an ICD and 59% of those with CRT were enrolled in period 4; the remaining were implanted in patients enrolled in previous periods, who were still actively followed up when the devices became available.
Changes in Functional Status and Reverse Remodeling
On average, patients enrolled in periods 3 and 4 improved their functional status during follow-up, whereas those enrolled earlier showed symptomatic progression ( Figure 2 ). Improvement in systolic LV function compared with baseline was observed in all groups, although most evident in periods 3 and 4. Likewise, a reduction in end-diastolic diameter index occurred to a greater extent in those patients enrolled most recently ( Figure 2 ). This was paralleled by a less common occurrence of worsening mitral regurgitation after 1990 (33% in period 1; 37% in period 2; 28% in period 3; and 11% in period 4; overall P<0.0001).
Long-Term Outcome and Predictors of Risk
During an average follow-up of 8.8±6.3 years, 271 patients (45%) reached the combined end point including all-cause mortality and HTx. Of these, 142 patients (23%) died because of refractory HF, 71 (12%) because of SD, 22 (4%) died of noncardiac causes, and 36 patients (6%) underwent HTx. Overall survival was 79% and 63% at 5 and 10 years, respectively. There was marked and progressive improvement in outcome from periods 1 to 4 for all end points (Figure 3) . When adjusted for age, sex, NYHA class, LVEF, and left atrial diameter index, event-free rates for the combined end point (all-cause mortality and HTx) at 5 years were 62%, for patients enrolled in period 1; 74% for period 2; 84% for period 3; and 93% for period 4 ( Figure 3A) . At multivariate analysis, an earlier enrollment period proved the most powerful predictor of the combined end point, independent of age, NYHA functional class, LVEF, left atrial diameter index, and sex (Table 3 ). Of note, each enrollment period was associated with a 42% reduction in risk compared with the previous one (hazard ratio, 0.58; 95% confidence interval, 0.50-0.67; P<0.001).
Likewise, an earlier period of enrollment proved a potent independent predictor of refractory HF death and SD. Risk of refractory HF mortality decreased (53%, 74%, and 90% in periods 2, 3, and 4, respectively) compared with period 1. Conversely, likelihood of SD declined sharply in patients enrolled after 2000, with a 87% risk reduction in period 4 compared with period 1. Notably there was also a trend of risk reduction from 1991 to 2000 (48%; P=0.09; Figure 3B and 3C).
Discussion
The present study demonstrates that the long-term prognosis of patients with IDCM has radically improved during the past 30 years, in terms of overall mortality, refractory HF death, and SD, reflecting continuing progress in pharmacological and device-based management. 19 Among our patients, each of 4 consecutive HF management eras implied a 42% reduction in mortality compared with the previous one, paralleled by greater degrees of reverse LV remodeling. 21 As a consequence, patients enrolled during the past decade, maximally treated with ACEI/ARBs and β-blockers and with unrestricted access to ICD/CRT, showed a 86% relative risk reduction in cardiovascular mortality compared with those enrolled before 1985, who were essentially managed with diuretics and digoxin. 20
Causes of Death: Changing Patterns Over Time
With regard to specific causes of death, the greatest reduction in refractory HF mortality was observed in the transition from periods 1 to 2 after the introduction of ACE inhibition; thereafter, HF death rates declined at a relatively constant rate. Conversely, marked and progressive impact on SD was evident in the transition to periods 3 and 4. Such advantageous trend of SD mortality reflects both the introduction of the ICD/CRT and the complete penetration of β-blocker treatment for HF in real-world practice. Indeed, because of the relatively small number of patients receiving ICD and ICD/CRT in our cohort, the fall in SD rates suggests a crucial prophylactic role of β-blockers. Consistent with this concept, Zecchin et al 22 have recently demonstrated the efficacy of optimized pharmacological treatment in reducing SD risk of IDCM. In their cohort, accurate titration of ACEI/ARBs and β-blockers led to a substantial improvement in the clinical and instrumental profile of patients with IDCM initially meeting the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) 23 criteria for prophylactic ICD implantation, two thirds of whom did not retain such indication at 6 months. Of note, the long-term outcome in this subgroup was comparable with that of patients with IDCM without SCD-HeFT criteria at enrollment. 22 Of note, similar results in patients with new-onset HF and severely depressed LVEF have been recently reported by Teeter et al. 24 
Impact of Clinical Setting on Pharmacological Therapy Implementation
HF treatment is constantly evolving and has led to remarkable achievements during the past decades. The use of neurohormonal inhibitors has become established during the past 2 decades, following major randomized clinical trials [25] [26] [27] [28] [29] [30] [31] [32] and their subsequent impact on international HF guidelines. 19, 33, 34 Compared with the early observations from the 1980s, when HF treatment was virtually confined to diuretics and digoxin, the 1990s have seen an explosion in the use of neurohormonal blockers: an extensive analysis by Stevenson et al showed that 86% of patients with HF were treated with ACEI after 1990 compared with 46% before 1990. 35 Nonetheless, the use of evidence-based pharmacological therapies in the real world has consistently failed to reach the rates reported in landmark randomized clinical trials. The EuroHeart Failure Survey, 36 investigating the clinical profile and treatment of >11 000 patients hospitalized for or with HF in 115 hospitals from 24 European countries between 2000 and 2001, showed that diuretics were still the most widely used agents in HF, prescribed in 87% of patients at the time, followed by ACEI (62%), β-blockers (37%), cardiac glycosides (36%), nitrates (32%), calcium channel blockers (21%), and spironolactone (20%). Notably only 17.2% of patients received the combination of diuretic, ACEI, and β-blockers. These rates have significantly improved in more recent HF registries, such as the S-HFR registry 37 or the EURObservational Research Programme: the Heart Failure Pilot. 38 Yet, in the S-HFR registry, as many as 18% of patients with HF did not receive ACEI/ ARBs, whereas 11% did not receive a β-blocker in the absence of any reported contraindication or side effect. Similar results originated from other extensive studies of HF cohorts showing that, in spite of the widely available evidence-based international treatment guidelines, recommended therapies are slowly adopted and inconstantly applied in clinical practice, with considerable proportions of eligible patients failing to receive optimal treatment. 39, 40 Conversely, our observations support the view that, in appropriate settings, the treatment rates and benefits of controlled randomized HF trials can be replicated in the real world. 41 The present IDCM cohort is representative of those seen at other community hospitals, in that ≈95% of our patients were from a welldefined geographic region in Central Italy, most of them having lived virtually their entire life in Tuscany. All patients were systematically followed up on a 6-month basis by the same team >3 decades, providing a high level of continuity of care during this extended time period and allowing continuous reassessment of risk profile and management of the primary condition as well as cardiovascular risk factors and comorbidities. This provided the opportunity to gradually optimize pharmacological therapy, including uptitration of ACEI/ARBs and β-blockers to the maximum tolerated dosage. 19 It is noteworthy that 92% and 57% of the overall population received ACEI/ARBs and β-blockers during the whole study period, reflecting stringent implementation of international guidelines even in the earliest cohorts, as soon as new treatments became available. In the past decades, these rates were as high as 97% and 86%, respectively, resembling those of landmark HF randomized control trials, rather than most HF surveys and registries. 36 However, our data are consistent with selected reports from dedicated tertiary hospital settings based on patients with chronic systolic HF because of ischemic heart disease. 42 Overall, these findings considerably expand previous observations showing favorable temporal trends in the outcome of IDCM and HF, based on smaller cohorts and less extended follow-up. Matsumura and Kubo 9,10 have shown significant improvement in the prognosis of a relatively small group of Japanese patients with IDCM, partly explained through an increased use of ACEI/ ARBs and β-blockers and a declining use of class Ia/Ib antiarrhythmic drugs after the 1990s, and a similar trend was observed by Aleksova et al 11 in a study focusing mainly on asymptomatic patients with IDCM without prior history of HF.
Changes in Demographics Among Enrollment Periods
It is important to acknowledge that, in our IDCM cohort, patients enrolled later had a less severe profile in terms of symptoms, LV size and function. This trend presumably reflects increasing awareness of the disease and availability of more sensitive diagnostic tools and may have contributed to the reduction in mortality observed during the years, resulting in an overestimation of benefits related to treatment. However, this trend is counterbalanced by the more advanced age at enrollment of the most recent groups. Although it is virtually impossible to quantify the net result of these trends on outcome, their opposite prognostic weight is likely to limit their combined effect substantially. In our multivariate models, the enrolment period proved to be a very potent predictor of outcome independent of the most relevant baseline clinical and demographic features including well-recognized prognostic factors (ie, age, sex, NYHA functional class, LV and left atrial diameters, LVEF, and degree of functional mitral regurgitation). [43] [44] [45] [46] [47] Thus, it is plausible to attribute most of the survival benefit observed to improvements in management rather than to the evolving patient demographics.
Conclusions
The evolution of evidence-based treatment has led to progressive improvement in the prognosis of IDCM, with dramatic reduction in heart failure-related mortality and SD during the past 3 decades. In the appropriate setting, the benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored and systematic follow-up providing long-term continuity of care.
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